Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - August 2012

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Albuterol and Ipratropium
Artemether and Lumefantrine
Atomoxetine
Bupropion
Captopril
Certolizumab
Cladribine
Cyclosporine
Delavirdine
Duloxetine
Efavirenz
Emtricitabine- Rilpivirine- Tenofovir
Enfuvirtide
Etravirine
Felbamate
Fesoterodine Fumarate
Gabapentin
Ipratropium Bromide
Ivacaftor
Lamotrigine
Linagliptin
Lisinopril
Lisinopril and Hydrochlorothiazide
Maraviroc
Mometasone Furoate and Formoterol Fumarate
Moxifloxacin
Norelgestromin and Ethinyl Estradiol
Olanzapine
Olanzapine and Fluoxetine
Oxaliplatin
Paliperidone Palmitrate
Panitumumab Injection
PEG-3350 and Minerals
Perflutren Protein-Type A Microspheres
Pramipexole
Raltegravir
Ranibizumab
Rilpivirine
Sevoflurane
Sildenafil
Solifenacin
Sorafenib
Tenofovir
Tolterodine
Trospium Chloride
Valsartan
Valsartan and Hydrochlorothiazide
Venlafaxine

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Complete Hypertension Guide: Control, Causes and Prevention.
Stay Connected
Available on the Android Market Available on the App Store